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Acinetobacter baumannii is a significant cause of opportunistic hospital acquired infection and has 
been identified as an important emerging infection due to its high levels of antimicrobial resistance. 
Multidrug resistant A. baumannii has risen rapidly in Vietnam, where colistin is becoming the drug of 
last resort for many infections. In this study we generated spontaneous colistin resistant progeny (up to 
>256 μg/μl) from four colistin susceptible Vietnamese isolates and one susceptible reference strain (MIC 
<1.5 μg/μl). Whole genome sequencing was used to identify single nucleotide mutations that could be 
attributed to the reduced colistin susceptibility. We identified six lpxACD and three pmrB mutations, 
the majority of which were novel. In addition, we identified further mutations in six A. baumannii genes 
(vacJ, pldA, ttg2C, pheS and conserved hypothetical protein) that we hypothesise have a role in reduced 
colistin susceptibility. This study has identified additional mutations that may be associated with 
colistin resistance through novel resistance mechanisms. Our work further demonstrates how rapidly 
A. baumannii can generate resistance to a last resort antimicrobial and highlights the need for improved 
surveillance to identified A. baumannii with an extensive drug resistance profile.
Acinetobacter baumannii is emerging worldwide as a hospital acquired pathogen infecting critically ill patients. 
In susceptible individuals A. baumannii can cause a range of infections including pneumonia, bacteraemia, men-
ingitis, blood stream infections and urinary tract infections1,2. On rare occasions A. baumannii has been linked 
to infective endocarditis3,4. A. baumannii can be a serious complication of serious trauma including cellulitis and 
soft-tissue infection5 as exemplified in military personnel returning from Iraq6 and Vietnam7. In addition, it is 
currently estimated to be responsible for 1 in 5 cases of ventilator-associated pneumonia (VAP) in Europe8.
The rapid emergence of A. baumannii has been associated with increasing resistance against the majority of 
currently used antimicrobials. In our previous study, conducted in an ICU in southern Vietnam over an 11-year 
period (2000–2011), we found that A. baumannii had become the principle pathogen causing VAP; this increase 
in prevalence was concurrent with the emergence and maintenance of resistance to carbapenems9. The ability 
of A. baumannii to develop broad spectrum resistance to antimicrobials through intrinsic and acquired anti-
microbial resistance means that treating persistent A. baumannii infections is a significant clinical challenge10. 
Resistance to carbapenems, such as meropenem and imepenem, which were considered to be the “gold standard” 
for the treatment of A. baumannii infections11,12, has resulted in colistin, a member of the polymyxin group of 
antimicrobials, becoming the last treatment option. Colistin is, therefore, a key drug in treating and controlling 
many hospital acquired infections due to multiresistant Gram-negative bacteria.
The action of colistin is similar to that of a detergent. The outer membrane of the bacterial cell is disrupted 
through electrostatic binding of positively charged regions of the colistin and negatively charged regions of the 
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hydrophilic lipid A component of lipopolysaccharide (LPS)13. This disruption of the lipid A component of the LPS 
induces a loss of integrity in the cell membrane and ultimately cell death. However, a reduction in the net negative 
charge of the LPS through modifications in lipid A decreases the binding potential of colistin to bacterial mem-
brane, which leads to reduced susceptibility against colistin14. The first genetic mechanism of colistin resistance 
to be reported was the pmrAB two-component system15. In Salmonella, PmrAB alters expression of the lipid A 
modification genes in response to environmental pH, Fe3 + and Mg2 + levels16,17. PmrA-regulated resistance in 
Salmonella results in the modification of lipid A with either 4-deoxy-aminoarabinose (Ara4N) or phosphoetha-
nolamine. However, A. baumannii lacks the Ara4N biosynthesis and/or attachment genes. Laboratory induced 
colistin resistance in A. baumannii has been demonstrated to be through non-synonymous mutations in both 
pmrA or pmrB, but not pmrC15,18. Adams et al. also showed that these mutations were clinically relevant through 
identification of a non-synonymous mutation in pmrB in clinical A. baumannii isolates at the same residue as in 
one of the laboratory induced isolates15. PmrA is responsible for auto-regulation of the operon and it has also been 
demonstrated that PmrA up-regulation is required for resistance14,15 but this may not be due to non-synonymous 
changes in the operon19. An alternative but less common mechanism of colistin resistance is through mutations 
in the lpx lipid A biosynthesis genes20. Mutations within lpxACD result in total loss of lipid A production and 
therefore LPS20. Although the cells remain viable there was an increased susceptibility to other antimicrobials, 
surprisingly clinical colistin resistant isolates with these mutations have been isolated20. Recently a TnSeq analysis 
of colistin resistance identified over 30 genes involved in inducible colistin resistance21. The study also identified 
that a lpsB knock-out, involved in LPS core biosysnthesis, increased sensitivity to colistin21. Phenotypically these 
mutations also have been shown to increase susceptibility to other antibiotics, in particular aminogylocides as 
well as phenol based biocides18. Analysis of the effect of these mutations on virulence in the Galleria mellonaria 
model has shown that, in some cases, virulence was not reduced18. Alarmingly a recent Chinese study identified 
plasmid borne phosphoethanolamine transferase enzyme (mcr-1) that conferred colistin resistance to E. coli22. 
The mcr-1 gene has subsequently been identified in other countries including Vietnam23 where it was found with 
other AMR genes within pigs destined for food. Currently this has not been identified in A. baumannii but this 
this would appear to be just a matter of time.
Here we aimed to explore potential mechanisms of colistin resistance in A. baumannii by combining 
laboratory-induced resistance with high-throughput genome sequencing to identify subtle genomic changes 
resulting in reduced sensitivity to colistin. Previously reported colistin resistance mechanisms as well as several 
novel genetic targets were identified. A. baumannii can rapidly develop colistin resistance through multiple mech-
anisms that would be difficult to monitor through simple molecular diagnostic tests and has important implica-
tions for the future treatment of this rapidly emerging pathogen.
Results
Whole genome analysis of four Vietnamese A. baumannii clinical isolates. To elucidate how 
de novo mutations play a role in colistin resistance in A. baumannii we selected four colistin susceptible clin-
ical isolates from patients with culture confirmed VAP in the Hospital for Tropical Diseases in Ho Chi Minh 
City between 2009 and 20119 (Table 1). Additionally, the fully sequenced colistin susceptible A. baumannii 
ATCC19606 (CGN-35) was used24. Antimicrobial susceptibility testing showed that BAL266 was susceptible to 
the majority of antimicrobials tested (with the exception of ampicillin), while BAL062 and BAL242 and BAL255 
were resistant to the majority of antimicrobials tested (Table 1). In addition, BAL255 was found to contain (by 
PCR amplification prior to genome sequencing) the blaNDM-1 gene, facilitating high-level resistance to carbapen-
ems and third generation cephalosporins.
Draft genome sequences were produced, assembled and annotated for all five A. baumannii isolates. A 
multi-locus sequence type (MLST) BLAST database was used to derive the isolates sequence type (ST) (Table 2). 
BAL062 was identified to be an ST136 strain, an ST that was first identified in China. Furthermore, BAL242 
belonged to ST493 (first identified in Vietnam), BAL255 belonged to ST355 (first identified in USA) and BAL266 
was a unique ST (ST585), with no comparable isolates in the A. baumannii MLST database. Lastly ATCC19606 
was identified to be a likely recombinant and contained a novel combination of previously identified alleles that 
contradicted the A. baumannii MLST database (Table 2). The blaOXA-51-like β -lactamase gene was identified by 
PCR25 in all four Vietnamese A. baumannii strains (Table 1). However, genome sequences further refined the pres-
ence of these genes to the blaOXA-51-like loci; blaOXA-66, blaOXA-70, blaOXA-78 and blaOXA-98 (Supplementary Table 1). 
The A. baumannii strain MDR-TJ26, a multidrug resistant (MDR) strain isolated in Tianjin, China was found to 
harbour a blaOXA-23 on a plasmid. During analysis of BAL062 and BAL242, the blaOXA-23 gene was identified but 
not the MDR-TJ-like plasmid, suggesting a chromosomal location, or an alternative resistance plasmid structure, 
for this gene in these organisms.
Isolate Date AMP TZP IMP AMK OFX CAZ CRO SXT FEP GEN CST NDM -1 OXA -51 OXA -23 OXA -24 OXA -58
BAL 062 Apr-09 R R R R R R R R R R S – + + – –
BAL 242 Jan-11 R R R R R R R R R R S – + + – –
BAL 255 Feb-11 R S R R R R R R R R S + + – – + 
BAL 266 Feb-11 R S S S S S S S S S S – + – – –
Table 1.  Antimicrobial susceptibility profiles of the parent A. baumannii strains used in this study. AMP; 
ampicillin, TZP; piperacillin/tazobactam, IMP; imipenem, AMK; amikacin, OFX; Ofloxacin, CAZ; ceftazidime, 
CRO; ceftriaxone, SXT; co-trimoxazole, FEP; cefepime, GEN; gentamycin, CST; colistin.
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A. baumannii MDR-TJ was used as a reference sequence to identify the compendium A. baumannii of anti-
microbial resistance (AMR) genes harboured by the Vietnamese strains (Supplementary Table 1)26,27. Analysis of 
the four Vietnamese A. baumannii strains and ATCC19606 found that many previously described A. baumannii 
AMR genes were highly conserved within these genetically variable isolates (Supplementary Table 1). Notably, the 
gyrA mutation S81L in A. baumannii MDR-TJ27, which induces reduced susceptibility against the fluoroquinolo-
nes, was additionally present in BAL062, BAL242 and BAL255. Furthermore, in comparison to A. baumannii 
MDR-TJ strain BAL255 contained an additional gyrA mutation, R442L, which may have sequential effect on 
increasing the Minimum Inhibitory Concentration (MIC) against fluoroquinolones.
Analysis of mutations in colistin resistant progeny strains. A series of longitudinal (five days) 
sub-culturing experiments was performed to induce and increase the MIC against colistin in the four selected 
Vietnamese clinical A. baumannii isolates and ATCC19606. During these experiments the organisms were inde-
pendently exposed to increasing concentrations of colistin. Firstly, the MIC against colistin was determined for 
all strains (Day 1 in Table 3) and then they were independently cultured on Mueller-Hinton agar supplemented 
with several differing concentrations of colistin (0.5, 1, 2, 4, 8, 16, 32 and 64 μ g/μ l). More than one colony growing 
on the highest concentration of colistin was selected and their MICs against colistin were measured. These strains 
were then independently sub-cultured on a higher range of colistin concentrations and again the organisms grow-
ing on the highest concentration of colistin were selected. After five days of sub-culture on increasing concen-
trations of colistin we had produced more than 30 strains that had MICs against colistin of > 256 μ g/μ l. Maximal 
daily MIC for each strain is shown in Table 3 and we were able to generate colistin resistant mutants (according 
to the current colistin resistant breakpoint as determined by British Society for Antimicrobial Chemotherapy 
(≥ 8 μ g/μ l)) within three days for all five isolates.
Fifteen progeny colonies from the sub-culturing experiments, with a range of MICs against colistin, were fully 
genome sequenced (Table 4, Supplementary Table 2). Sequences from progeny colonies were aligned to the draft 
respective parent strains genome sequences to identify the induced genetic variation that may be responsible for 
the observed increase in MIC against colistin (Table 4). Over the period of five days of subculture from within 
the selected organisms we observed 17 different non-synonymous mutations and a single synonymous intergenic 
mutation in comparison to the parent isolates (Table 4).
We first compared the pmrAB genes, which are known hotspots for mutations facilitating elevated MICs 
against colistin. On analysis of pmrAB we found that this region exhibited 100% DNA sequence similarity in 
all strains prior to experimentation. Notably, after five days of subculture we observed no mutations in pmrA 
compared to the parent strains. Similarly, the DNA sequence of pmrB was identical in all parental isolates with 
the exceptions of a non-synonymous H440N substitution in ATCC19606 and an A444V inducing substitution in 
BAL062 and BAL242 in comparison to the A. baumannii MRD-TJ. These mutations were observed at the extreme 
3′ end of the coding sequence and were predicted not to result in a change of susceptibility against colistin. 
Indeed the entire collection of parent isolates had an MIC of 1.5 μ g/ml or below. In the resulting progeny with 
elevated MICs to colistin, the only strains to harbour non-synonymous mutations in pmrB originated from the 
parent BAL266 (Table 4, Supplementary Table 2). A pfam domain search of PmrB indicated that two histidine 
kinase domains are present between residues 218–279 and 326–436. Markedly, only PmrB from BAL266-Day3 
contained an amino acid change (E229D) within these motifs, yet isolates with higher MIC values contained 
Isolate Bp (GC%) Coverage CDSs gltA gyrB gdhB recA cpn60 gpi rpoD ST Origin
BAL 062 4,028,838 (38.99) 41.2x 3,960 1 3 3 2 2 16 3 ST136 This study
BAL 242 3,912,277 (38.91) 33.6x 3,786 1 15 3 2 2 106 3 ST493 This study
BAL 255 3,953,867 (39.02) 64.5x 3,752 1 81 11 48 18 114 43 ST355 This study
BAL 266 3,774,702 (38.86) 43.8x 3,645 1 15 13 12 4 163 2 ST585 This study
ATCC19606 3,974,237 (39.06) 49.6x 3,894 1 10 8 6 1 110 14 New [34, 35]
Table 2.  Genome characteristics of the sequenced A. baumannii isolates in this study. Bp = approximate 
genome size in base pairs, CDSs = Prokka predicted number of coding sequences, ST = Multilocus sequence 
typing (MLST) sequence type. gltA, gyrB, gdhB, recA, cpn60, gpi and rpoD are MLST scheme genes, unique 
alleles given unique number and combination of seven alleles define a strain ST.
Isolate
Minimum inhibitory concentration against colistin μg/ul
Day 1 Day 2 Day 3 Day 4 Day 5
BAL 062 0.5 0.75 > 256 > 256 > 256
BAL 242 0.5 32 48 192 192
BAL 255 0.5 0.75 48 128 > 256
BAL 266 1.5 6 64 96 128
ATCC19606 0.5 16 > 256 > 256 > 256
Table 3.  A. baumannii susceptibilities to Colistin in vitro.
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non-motif located PmrB mutations, for example R134C (BAL266-Day4), Y194S (BAL266-Day5) and G315S 
(BAL266-Day4 and BAL266-Day5) (Table 4).
The gene pmrC was present in all parental strains, however an accurate assembly of the gene sequence was 
confounded by the presence of a highly similar pmrC-compensating gene, eptA. Gene eptA encodes a phosphoe-
thanolamine transferase, which is not proximate to the pmrAB locus28. Gene eptA is present in some strains and 
can occur in more than one copy, which would further complicate genome assemblies, and may induce a pheno-
typic effect on colistin susceptibility. BAL062, BAL266 and ATCC19606 had a single copy of eptA. BAL242, due 
to read depth and single nucleotide polymorphisms (SNPs) appears to have at least two copies despite a single 
copy in the assembly. BAL255, despite the lack of eptA in the assembly may have a copy as the sequence reads map 
against the A. baumannii MDR-TJ (CP003500) eptA.
The genes lpxA and lpxD, which encode acyltransferases for lipid A biosynthesis, are located in the A. baumannii 
genome, with only a single gene (fabZ) separating them; conversely, lpxB and lpxC, which are again involved 
in lipid A biosynthesis, are encoded in separate chromosomal regions. For example, in the completed 
A. baumannii 1656-2 genome29, using the systematic gene numbering, lpxA, lpxD, lpxB and lpxC equate to coding 
sequence number 2552, 2554, 2156 and 3579 respectively. Within the collection of colistin resistant progeny 
we were able to identify mutations in lpxACD but not lpxB (Table 4). Two BAL242 progeny colistin resistant 
isolates (BAL242-Day3 and BAL242-Day5) had an identical SNP in lpxA that resulted in the formation of a 
premature stop codon, truncating the protein at 325 amino acid residues. BAL255-Day3 had a non-synonymous 
A141T mutation in lpxA, falling within one of three predicted transferase hexapeptide repeats and a UDP 
N-acetylglucosamine O-acyltransferase (Domain 2). In lpxD three independent mutations resulted in abrogated 
LpxD at residue 325 (BAL062-Day5, BAL242-Day2 and BAL266-Day3); a loss of an adenine resulting as a T319R 
(BAL062-Day5 and BAL242-Day2) and a caa/Q to taa/stop mutation (BAL266-Day3). LpxC mutations occurred 
in BAL266-Day3 with a P30L substitution but a frameshift in ATCC19606-Day5 resulted in a truncated protein 
of 127aa (Table 4).
Lastly, additional analysis of the sequence data identified a number of other, not previously described, muta-
tions that were associated with a colistin resistance phenotype: i) zndP and pldA are co-located in a putative 
operon; BAL255-Day4 had a frameshift in zndP which would result in a highly truncated protein (only 165/992 aa) 
and BAL266-Day3 (209/383) had mutation in pldA, ii) vacJ mutations occurred as frameshifts in both 
BAL242-Day5 and ATCC19606-Day3 resulting in truncated proteins of 257 and 135 aa respectively, iii) a N138S 
Strain MIC to Colistin (ug/ml) LpxA (262) LpxC (300) LpxD (356) PmrB (444) PheS (326) ZndP (992) PldA (383) VacJ (299) 135 (255) Ttg2C (226)
BAL062 0.5
BAL062-Day2 0.75




BAL242-Day2 32 T319R (325)†
BAL242-Day3 48 STOP (229)
BAL242-Day5 192 STOP (229) Q249T (257)†
BAL255 0.5
BAL255-Day2 0.75
BAL255-Day3 48 A141T H242L*
BAL255-Day4 128 H242L* F149L (165)†
BAL255-Day5 > 256 H242L* W179C (186)†
BAL266 1.5
BAL266-Day2 6
BAL266-Day3 16 P30L T200T (209)†
BAL266-Day4 96 R134C, G315S
BAL266-Day5 128 Y194S, G315S N138S
ATCC19606 0.5
ATCC19606-Day3 > 256 R166N (135)†
ATCC19606-Day5 > 256 Y111C (127)†
Table 4.  Summary of mutations in colistin resistant progeny. 135 = A. baumannii AB307-0294 CDS 
ABBFA_000135 homologue annotated as ‘hypothetical protein. * indicates a synonymous change gca- > gcg 
(A-> A) was also present. †Denotes a frameshift due to a nucleotide deletion/insertion resulting in a truncated 
protein, (xx) indicates the size of full/truncated protein in amino acids, STOP indicates a C to T SNP that 
generates a TAA stop codon.
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in pheS is involved in phenylalanyl-tRNA synthetase the mutation, iv) two hypothetical proteins also demon-
strated significant truncation due to frameshifts; BAL255-Day5 Ab09_2943 and ttg2C (Table 4). Ab09_2943, an 
orthologue to A. baumannii 307-0294 CDS ABBFA_00013530 and conserved in all five strains. Ab09_2943 is a 
conserved hypothetical protein with similarity to a signal peptide protein of the putative MetA-pathway of phenol 
degradation30. ttg2C was similar to a toluene tolerance efflux ABC transporter periplasmic substrate-binding 
protein.
Discussion
The rise of A. baumannii in Vietnam has been accompanied by the rapid emergence of antimicrobial resistance 
in this problematic environmental bacteria resulting in colistin being a last-resort antibiotic9. As resistance to 
colistin is primarily caused by spontaneous mutation as opposed to the acquisition of horizontally transferred 
resistance genes, we investigated which mutations could be induced under laboratory conditions in four MDR 
isolates of A. baumannii. We used whole genome sequencing to investigate MLST, antibiotic resistance gene con-
tent and mutations associated with colistin resistance.
On extracting the MLST alleles from the assembled genomes and inferring sequence type we found that 
each of the Vietnamese clinical isolates had a differing ST. ATCC19606, originally isolated in 1911 in Delft, The 
Netherlands, was present in the pubMLST database as an ST26 and used a control for the study (http://pubmlst.
org/abaumannii/). However, analysis of ATCC19606 genome identified this strain as a novel/undocumented ST 
consisting of a new combination of known alleles. An independent shotgun assembly of the ATCC19606 genome 
was available at NCBI (http://www.ncbi.nlm.nih.gov/Traces/wgs/?val = ACQB01) and analysis of this genome 
assembly also produced an identical allele combination. The ATCC19606 ST and ST26 only share two alleles (gltA 
and gyrB) but gdhB differs by four SNPs, and recA, cpn60, gpi and rpoD all by one SNP. It is clear that the alleles 
are closely related so this discrepancy may be due to changes induced during long-term storage and sub-culture 
of this strain since it entered the ATCC.
Analysis of the Vietnamese clinical strains showed that many of the antimicrobial resistance associated genes 
were conserved between strains and found to be additionally present in the Chinese MDR-TJ strain27. BAL266 
was phenotypically sensitive to all antimicrobials tested and was highly similar to the 1911 ATCC19606 AMR 
genotyping profile. BAL242 contained all MDR-TJ AMR genes except aacC1 gentamycin resistance although 
it was BAL255 that had the blandm-1 genotype, giving high level resistance to carbapenems and third generation 
cephalosporins.
The association of mutations in the putative two component regulatory system PmrAB with resistance to 
colistin in A. baumannii was first described in 200915. No mutations were observed within PmrA (Table 4), a 
response regulator which auto-regulates PmrABC expression; the same was observed for PmrC. The gene pmrB, 
a sensor kinase, has previously been shown to contain non-synonymous SNPs, frameshifts and deletions15,28. This 
study has identified further mutations associated with resistance against colistin in PmrB (Table 4). This suggests 
that variation within the sensor transcriptional regulator is the common mechanism for colistin resistance by 
altering gene expression. The loss of lipid A, and ultimately LPS, through mutations in the lpxACD genes in 
laboratory culture results in lower fitness and a low virulence potential of the organism31, however a few clinical 
isolates have been shown to possess lpxACD mutations20. All the lpxACD mutations generated in this study, with 
the exception of an LpxC P30L, have not been previously induced20.
Supplementary to mutations in the pmrAB and lpxACD genes, which have previously been demonstrated to 
have a role in colistin resistance, mutations in several other genes were additionally observed. The identified genes 
(e.g. vacJ and pldA) have not previously been implicated in having a role in changing antimicrobial susceptibil-
ity, however we note that the majority of the target genes are associated with the outer membrane, the target of 
polymyxins. In some of the sequenced strains an increase in the MIC against colistin can only be explained by 
these additional mutations. For example, both BAL 242-Day3 and BAL 242-Day5 had a premature stop codon in 
lpxA stop, but differed considerably in MIC (48 μ g/μ l and192 μ g/μ l, respectively). The only additional difference 
between these strains was frameshift in vacJ in BAL 242-Day5 (Table 4). Gene vacJ is a highly conserved and 
widely distributed outer membrane lipoprotein, important for virulence in a number of Gram-negative path-
ogens32,33. VacJ is frequently associated with Vps (Mla) to form the Vps-VacJ ABC transporter system, which 
is responsible for maintaining outer-membrane asymmetry (LPS at the outer leaflet and phospholipids at the 
inner leaflet)34. Bacteria accumulate phospholipids in the outer leaflet, for example after exposure to chemical 
treatments, disrupting LPS organization and increasing sensitivity to toxic compounds34. VacJ was found to be 
upregulated in a putative outer membrane protein mutant of S. enterica serovar Typhimurium that resulted in 
resistance against ceftriaxone35. Mutations within the vps-vacJ transporter genes result in increased sensitivity 
to Sodium dodecyl sulfate (SDS) in both E. coli34 and Shigella flexneri36. A spontaneous pldA mutation, result-
ing in increased transcription, restored the SDS insensitivity34. PldA has been suggested to remove phospho-
lipids in the outer leaflet of the outer membrane, maintaining asymmetry, an activity which has been shown to 
increase in bacteria with destabilised outer membranes37. In this study two vacJ mutants and a pldA mutation 
were identified in colistin resistant progeny, predicting that outer asymmetry maintenance is related to colistin 
susceptibility. Interestingly, pldA is downstream of zndP, in which another putative colistin resistance associated 
mutation was identified. ZndP is a putative zinc-dependant peptidase, and when linked to PldA, may have a role 
in outer membrane processing. Ttg2C is a putative solvent/toluene tolerance efflux ABC transporter periplasmic 
substrate-binding protein which has been shown to be upregulated in Pseudomonas putida KT2440 in response 
to phenol exposure38. Phenol is an organic solvent that solubilises the cell wall, the same mode of action as colis-
tin, and hence genes involved in phenol resistance may confer colistin resistance. Interestingly this study also 
identified VacJ amongst many upregulated proteins38. These additional genes were not identified as differentially 
expressed under NaCl induced colistin resistance21.
www.nature.com/scientificreports/
6Scientific RepoRts | 6:28291 | DOI: 10.1038/srep28291
Here we sought to induce and identify mutations associated with colistin resistance in A. baumannii. Taking 
several antimicrobial resistant, but colistin susceptible Vietnamese clinical isolates of A. baumannii, we induced 
rapid high-level resistance to colistin. In performing whole genome sequencing of colistin resistant A. baumannii 
strains we aimed to take a holistic approach to the genetics behind resistance. Previous studies have focused 
specifically on the PmrAB and LpxACD (for example18) but other studies have demonstrated other genes are 
involved (for example lpsB21). We have identified mutations within genes that can be hypothesised to play a role 
due to linkage to the other membrane.
In conclusion, colistin resistant A. baumannii can be generated rapidly in a laboratory. Heightened surveil-
lance in clinical laboratories and across international networks should be perform to detect these organisms rap-
idly when they arise and prevent their spread. Our work worryingly shows that colistin, a drug of last resort, may 
rapidly become ineffective, having serious implications for future treatment of infections caused by A. baumannii 
and other hospital acquired pathogens.
Methods
Bacterial identification and antimicrobial susceptibility testing. The reference A. baumannii Bouvet 
and Grimont strain from 1911 was purchased from ATCC (ATCC19606). Clinical bacterial strains were isolated 
from tracheal aspirates (TA) specimens taken from patients with suspected VAP in the adult ICU of the Hospital 
of Tropical Diseases in Ho Chi Minh City, Vietnam from January 2011 to June 2012 (Table 1). A. baumannii were 
identified using API20NE and confirmed by using a previously described PCR method to detect blaOXA-51, which 
is intrinsic to the species39. All A. baumannii isolates were stored in glycerol at − 80 °C until further analysis.
Antimicrobial susceptibilities were determined at the time of isolation by the modified Bauer-Kirby disk diffu-
sion method, as recommended by the CLSI guidelines (CLSI. 2011/2. Performance Standards For Antimicrobial 
Susceptibility Testing; Twenty-First Informational Supplement, CLSI document M100-S21, vol. 31, Clinical and 
Laboratory Standards Institute) and included Ampicillin (AMP-10 μ g), piperacillin/tazobactam (TZP-100/10 μ g), 
imipenem (IMP-10 μ g), amikacin (AMK-30 μ g), ofloxacin (OFX-5 μ g), ceftazidime (CAZ-30 μ g), ceftriaxone 
(CRO-30 μ g), co-trimoxazole (SXT-1.25/23.75 μ g), cefepime (FEP-30 μ g), gentamycin (GEN-10 μ g) and colistin 
(CST-10 μ g). Mueller-Hinton agar and antimicrobial discs were purchased from Unipath, Basingstoke, United 
Kingdom. For colistin (CST), imipenem (IMP), ceftazidime (CAZ), and ceftriaxone (CRO), minimum inhibitory 
concentrations (MICs) were determined by E-test based on manufacturer’s recommendations (AB Biodisk, Sweden). 
The results were interpreted as resistant or sensitive according to current CLSI guidelines. Escherichia coli  
ATCC 25922 was used as the control for these assays.
Induction of resistance. All clinical isolates were recovered from glycerol stock on Mueller-Hinton (MH) 
plates and colonies of each organism were suspended into 100 μ l of sterile phosphate buffered saline (PBS). To 
induce resistance to colistin 3 μ l of each suspension was inoculated on MH plates supplemented with differing 
concentrations of colistin (0.5, 1, 2, 4, 8, 16, 32 and 64 μ g/μ l) for five consecutive days or until the highest MIC to 
colistin was reached. The colistin concentration used in the inducement experiment varied among A. baumannii 
strains according to their corresponding MIC to colistin, which had been determined by E-test strip, and ranged 
from 1 x MIC to 8 x MIC for each strain. Colonies of each strain that were able to grow on MH plates with the 
highest colistin concentration for each day were inoculated in glycerol and stored at − 80 °C until DNA extraction.
Whole genome sequencing and analysis. Genomic DNA was extracted using the Wizard Genomic 
DNA Extraction Kit (Promega, Fitchburg, WI). The quality and concentration of the DNA were assessed using 
a Nanodrop bioanalyser spectrophotometer (Thermo Scientific, Delaware, USA). All isolates were sequenced 
on an Illumina MiSeq using the Nextera XT as per the manufacturers’ protocols. All samples were multiplexed 
and sequenced on a single MiSeq 2 × 151 bp run (EBI: PRJEB10709). Demultiplexed FASTQ files were quality 
controlled using Trimmomatic-0.30 [LEADING:3 TRAILING:3 SLIDINGWINDOW:4:20 MINLEN:36]40. Draft 
genomes were de novo assembled using VelvetOptimiser-2.2.5 (Victorian Bioinformatics Consortium, Australia) 
and Velvet 1.2.0941. Contigs from the sensitive parental strains were ordered by Abacas 1.3.142 using A. baumannii 
MDR-TJ (CP003500) as a reference. Contigs breaks were joined using IMAGE43. Derived progeny draft assembly 
contigs were ordered to the parental strain using Abacas. Genomes were annotated using Prokka and an custom 
Acinetobacter reference library44. Laboratory induced SNPs were identified by mapping progeny sequencing 
reads against the parental isolate using BWA45 and SAMtools46 [varFilter.pl]. All SNPs were manually checked. 
MLST was determined using BLAST47 and a custom allele database.
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